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Multiple early hospital cohorts of coronavirus disease 2019 (COVID-19) showed that patients 
with chronic respiratory disease were significantly under-represented.  We hypothesised that 
the widespread use of inhaled glucocorticoids was responsible for this finding and tested if 




We conducted a randomised, open label trial of inhaled budesonide, compared to usual care, 
in adults within 7 days of the onset of mild Covid-19 symptoms. The primary end point was 
COVID-19-related urgent care visit, emergency department assessment or hospitalisation. 
The trial was stopped early after independent statistical review concluded that study outcome 




146 patients underwent randomisation. For the per protocol population (n=139), the primary 
outcome occurred in 10 participants and 1 participant in the usual care and budesonide arms 
respectively (difference in proportions 0.131, 95% CI (0.043 to 0.218), p=0.004). The number 
needed to treat with inhaled budesonide to reduce COVID-19 deterioration was 8. Clinical 
recovery was 1 day shorter in the budesonide arm compared to the usual care arm (median 
of 7 days versus 8 days respectively, logrank test p=0.007). Proportion of days with a fever 
and proportion of participants with at least 1 day of fever was significantly lower in the 
budesonide arm. Fewer participants randomised to budesonide had persistent symptoms at 
day 14 and day 28 compared to participants receiving usual care. Budesonide was safe with 




Early administration of inhaled budesonide reduced the likelihood of needing urgent medical 
care and reduced time to recovery following early COVID-19 infection. 
(ClinicalTrials.gov number, NCT04416399) 
 





Research in context 
Evidence before this study 
The majority of interventions studied for the COVID-19 pandemic are focused on hospitalised 
patients. Widely available and broadly relevant interventions for mild COVID-19 are urgently 
needed.  
Added value of this study 
In this open label randomised controlled trial, inhaled budesonide, when given to adults with 
early COVID-19 illness, reduces the likelihood of requiring urgent care, emergency 
department consultation or hospitalisation. There was also a quicker resolution of fever, a 
known poor prognostic marker in COVID-19 and a faster self-reported and questionnaire 
reported symptom resolution. There were fewer participants with persistent COVID-19 
symptoms at 14 and 28 days after budesonide therapy compared to usual care. 
Implications of all the available evidence 
The STOIC trial potentially provides the first easily accessible effective intervention in early 
COVID-19. By assessing health care resource utilisation, the study provides an exciting option 
to help with the worldwide pressure on health care systems due to the COVID-19 pandemic. 
Data from this study also suggests a potentially effective treatment to prevent the long term 




COVID-19 is the most serious pandemic for over 100 years and with increasing mortality and 
morbidity worldwide. Other than age, obesity, and gender1,2, there are no clear predictors to 
forecast who will deteriorate needing hospital-based care. The onset of COVID-19 illness is 
almost always mild3 giving a potential window to intervene prior to the development of severe 
disease1,2.To date, the majority of studies have focussed on investigating and treating severe 
and hospitalized COVID-19 infection4. However, there is currently little knowledge on 
therapeutic targets in early COVID-19 infection to prevent progression and clinical 
deterioration, although investigation with targets such as monoclonal antibodies are being 
studied5.  
In early reports describing COVID-19 infection from China1,2, Italy6 and the United States7, 
there was a significant under representation of patients with asthma and chronic obstructive 
pulmonary disease (COPD) in patients hospitalized with COVID-19. We hypothesized that this 
may be due to the widespread use of inhaled glucocorticoids in these patients8. Furthermore, 
the main indication for the use of inhaled glucocorticoids in patients with asthma and COPD 
is to reduce exacerbations, which are recognized to be often viral in etiology9. In-vitro studies 
have shown that inhaled glucocorticoids reduce the replication of SARS-CoV-2 in airway 
epithelial cells10 in addition to the downregulation of expression of angiotensin converting 
enzyme-2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) genes which are critical 
for viral cell entry11. 
Here we present the analysis of the Steroids in COVID-19 (STOIC) trial, a phase 2 trial 
designed to evaluate the efficacy of a widely used inhaled glucocorticoid budesonide in 
individuals with early COVID-19 disease in the community. We examined the effect of inhaled 
budesonide on likelihood of urgent care or hospitalization, clinical recovery and parameters of 
physiology such as temperature and oxygenation. We also evaluated the effect of inhaled 






The STOIC trial is a randomised, open-label, parallel group phase 2 clinical trial conducted in 
the community in Oxfordshire, United Kingdom. Adults over the age of 18, with symptoms 
suggestive of COVID-19 (new onset cough, fever and/or anosmia) within 7 days were eligible 
for inclusion. Participants were excluded if they had recent use (within 7 days) of inhaled or 
systemic glucocorticoids or if there was a known allergy or contraindication to inhaled 
budesonide. Recruitment for the study was via local primary care networks, local COVID-19 
testing sites and via multi-channel advertising. Volunteers were able to contact the study staff 
using the advertised phone numbers or via e-mail and all participant information was publicly 
available on the study website (www.stoic.ndm.ox.ac.uk). The trial was registered on 
clinicaltrials.gov (NCT04416399). 
Study intervention and assessments 
Participants who met the inclusion criteria were randomised to usual care (UC) or  intervention 
with budesonide (BUD) dry powder inhaler (Pulmicort Turbuhaler, AstraZeneca) at a dose of 
800µg (2 puffs) twice a day. In the U.K., UC was supportive therapy with National Health 
Service (NHS) advising patients with COVID-19 symptoms to take anti-pyretics for symptoms 
of fever (products containing paracetamol, or non-steroidal anti-inflammatories such as aspirin 
and ibuprofen) and honey for symptoms of cough. Participants were seen at their homes at 
randomisation (day 0), day 7 and day 14 by a trained respiratory research nurse to obtain 
written informed consent, provide inhalers and to obtain (self-performed) nasopharyngeal 
swabs for SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) testing 
(see supplementary methods for further details). Each participant received a paper symptom 
diary, calibrated pulse oximeter and thermometer for daily home monitoring. All participants 
were telephone contacted daily to record oxygen saturations, temperature and assessed for 
any adverse events by the study team. Participants allocated BUD were asked to stop taking 
the inhaler when they felt they had recovered (self-reported symptom recovery) or if they hit 
primary outcome; and all participants ceased daily monitoring (including daily telephone calls) 
when symptoms had recovered (self-reported symptom recovery) or if the primary outcome 
was achieved. Finally, at day 28, all study participants were seen in the trial centre and serum 
SARS-CoV-2 antibody testing was performed.  
Outcomes 
The primary outcome was defined as COVID-19-related Urgent Care visits including  
Emergency Department assessment or hospitalization. During the pandemic, members of the 
public in the United Kingdom were encouraged to contact a government telephone advice line 
prior to attending the emergency department and COVID-19 specific general practice hubs 
were created for patients who were deteriorating at home, for medical treatment including 
transfer to hospital.  Secondary outcomes included clinical recovery as defined by self-
reported time to symptom resolution; viral symptoms measured by the Common Cold 
Questionnaire (CCQ)12 and the InFLUenza Patient-Reported Outcome (FLUPro®)13 
questionnaire; blood oxygen saturations and body temperature; and SARS-CoV-2 viral load. 
Randomisation  
Participants were randomly allocated to UC or BUD, stratified for participant age,(≤40 years/ 
>40 years) gender, and number of co-morbidities (≤1/ ≥2). The randomisation sequence was 
created using a random number generation function and allocation to each arm was performed 
through block randomisation in a 1:1 ratio. 
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Statistical Analysis 
The statistical packages R (R Core Team (2020). R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL 
https://www.R-project.org/), Gauss ((https://www.aptech.com/), and SAS v9.4 
(https://www.sas.com/en_us/home.html) were used. Descriptive statistics were used to 
describe variables between the groups in the BUD arm and the UC arm. Appropriate 
parametric or non-parametric statistical tests were performed. For continuous variables, the 
difference between treatments in the means or medians and the corresponding 95% 
confidence interval were reported. For continuous variables, fixed-factor ANCOVA models (t-
tests) adjusted for treatment, age group (> or <=40 years), sex, no. of comorbidities (<=1, >=2) 
and baseline or Wilcoxon rank sum tests were applied to compare the BUD and UC arm. For 
categorical variables the number (and percentage) of patients in each category were reported 
for each treatment group and chi-squared tests were used for comparing treatment arms. 
Confidence intervals for the difference in proportion was by normal approximation (Wald). 
Time to self-reported clinical recovery and FLUPro® symptom recovery were analysed using 
the Kaplan Meier method and presented as the median time to event with 95% confidence 
limits. Comparison were performed with a log rank test where participants with primary 
outcome were censored at Day 28 when not meeting the event.  Sensitivity analysis for 
participants with confirmed COVID-19 infection was also performed for the primary outcome. 
All tests were performed at a 5% 2-sided significance level and all comparative outcomes are 
presented as summary statistics with 95% confidence intervals and reported in accordance 
with the CONSORT Statement. Missing data from study visits and daily monitoring were 
handled by last observation carried forward (LOCF) for temperature, oxygen saturations and 
time to FLUPro® symptom resolution. For FLUPro® total score and individual domain time-
series plots, missing data was handled by LOCF or imputation of zero score when self-
reported symptom resolution. Less than 1% of data was determined as missing. Stochastic 
simulations of a “virtual” trial with the same study design, primary endpoint and duration, and 
community detection are presented in full in the  supplementary materials. P-values are 
reported to a maximum of 3 decimal places. Further full details are available in the 
supplementary material.  
Sample size estimation 
At study inception in March 2020 and using published data available at the time1,2, we 
assumed that 20% of all COVID-19 illness is severe and would require hospitalisation. Using 
80% power at 0.05 level, we required 199 patients in each arm to demonstrate a 50% 
reduction of urgent care visits or hospitalizations. The primary outcome was analysed for both 
the per-protocol (PP) and intention to treat (ITT) population. The PP population is defined as 
the population that received the study treatment and had at least 1 day of study observations;  
the ITT population is defined as all participants that were randomized to a study arm. 
Institutional Review 
The trial was sponsored by the University of Oxford, and was approved by the Fulham London 
Research Ethics Committee (20/HRA/2531) and the National Health Research Authority. The 
BUD was open label. All participants provided written informed consent. The study team 
requested an independent statistical monitoring committee review on the 9th of December 
2020 due to reduced recruitment after the second national lockdown in England; 
implementation of the COVID-19 vaccine; and ethical consideration of the primary outcome. 
A priori stop criteria were used to determine futility of further recruitment (see statistical 
analysis plan).  
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Role of funder 
The study was funded by the Oxford NIHR Biomedical Research Centre and AstraZeneca 
(Gothenburg, Sweden). The funders had no role in study design, data collection, data analysis, 
data interpretation, writing nor the decision to publish. The views expressed are those of the 





From the 16th July to the 9th December 2020, 146 participants were randomised, of which 139 
were in the PP analysis, with 70 and 69 in the BUD and UC arm respectively (see figure 1). 
Participant characteristics were similar between the study arms, as shown in table 1 (see 
supplementary table 1 for ITT population). SARS-CoV-2 infection was detected in 137 
participants (94%) measured by RT-PCR. Serological conversion was detected in 55% 
(67/122 samples). The median (IQR) duration of symptoms prior to randomisation was 3 (2 to 
4) days. The median (IQR) time to symptom resolution was 7 (5 to 11) days. BUD was taken 
for a median (IQR) duration of 7 (4 to 10) days.  
Conditional power 
Simulations using bootstrap was performed to determine the conditional power for an 
evaluation of an early stop, using the a priori decisions described in the supplement. Estimated 
power was >99% using both the total population (N=124) and, at the time of the simulation, 
sensitivity analysis for the known subgroup of SARS-CoV-2 positive patients (N=78). 
Primary outcome 
For the ITT population, the primary outcome occurred in 11 (15%) participants in the UC arm 
and 2 (3%) participants in the BUD arm (difference in proportion 0.123, 95%CI (0.033 to 
0.213), p=0.009). In the PP analysis, the primary outcome occurred in 10 participants (14%) 
in the UC arm versus 1 participant (1%) in BUD arm (difference in proportions 0.131, 95% CI 
(0.043 to 0.218), p=0.004) indicating a relative risk reduction of 91% for BUD. The number 
needed to treat with inhaled budesonide to reduce COVID-19 related urgent 
care/hospitalization was 8. Sensitivity analysis in participants with confirmed COVID-19, 8 
(14.1%) vs 1 (1.5%), showed that the difference in proportions was 0.125, 95% CI (0.035 to 
0.216), p=0.007. There was no difference in participants with a primary outcome event 
compared to those without (see supplementary table 2). For all primary outcome events, 3 
participants were symptomatically breathless with oxygen saturations below 94%; 1 
developed diabetic ketoacidosis; 1 developed acute kidney injury; 1 had suspected pulmonary 
embolism; 1 had suspected rib fractures; 3 were seen at least twice by an out of hours general 
practitioner (which included the 1 participant in the BUD arm); and 1 was seen by a paramedic 
crew on day 6 and subsequently seen again by a general practictioner on day 8 and sent to 
ED, where they were directly admitted to the Respiratory High Dependency Unit requiring 
continuous positive pressure ventilation for 8 days. All participants not admitted to hospital 
had daily telephone checks with the COVID Hub general practicitioner team.  
Secondary outcomes 
Self-reported clinical recovery was 1 day quicker with BUD compared to UC (median, 95%CI 
of 7 (6 to 9) days versus 8 (7 to 11) days, logrank test p=0.007, see figure 2). The mean (SD) 
time to recovery, in days was 8 (5) and 12 (8) in the BUD and UC arm respectively.  Further 
sensitivity analysis for clinical recovery in participants with confirmed SARS-CoV-2 showed a 
similar median (95%CI) times to recovery (7 (6 to 9) vs. 8 (7 to 10) days, p=0.012) (see 
supplementary figure 1). At day 14, self-reported symptoms were present in 10% (n=7) of 
participants randomised to BUD compared to 30% (n=21) randomised to UC (difference in 
proportion 0.204, 95%CI (0.075 to 0.334), p=0.003).  
The mean proportion of days with a documented fever (≥37.5 C) during the first 14 days, was 
2% (SD 6%) in the BUD and 8% (SD 18%) in the UC arms (Wilcoxon test, p= 0.051; Hodge-
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Lehmann median 0% (95% CI 0, 0)). The percentage of participants with at least 1 day of 
fever was 11% (n=8) and 23% (n=16) in the BUD and UC arm respectively (difference in 
proportion 0.067, 95% CI (-0.678, 0.242), p=0.076). Violin plots, showing the distribution of 
pooled highest temperatures are presented in figure 3,  demonstrating a statistically higher 
mean in the UC arm (mean difference 0.49, 95%CI 0.32 to 0.66, p<0.001). Temperature plots 
relative to the day of randomization showed that temperature fell quicker in the BUD compared 
to UC arm (see supplementary figure 2). The median (IQR) proportion of total days that 
participants required as-needed antipyretics (paracetamol, aspirin, ibuprofen) in the BUD and 
UC arms was  27% (0 - 50) and 50% (15 - 71) respectively (Wilcoxon test, p=0.025). 
Symptom resolution at day 14, as defined by the FLUPro® user manual, occurred in 82% 
(n=55) and 72% (n=49) of the BUD and UC arms respectively (difference in proportions 0.100, 
95% CI (-0.040, 0.241), p=0.166); whilst the median (95%CI) time to symptom resolution as 
measured by the FLUPro® was 3 (2 to 5) and 4 (3 to 6) days in the BUD and UC arms 
respectively (logrank test p=0.080, see supplementary figure 3). The mean change (95%CI) 
in FLUPro® total score between day 0 and day 14 in the BUD and UC are -0.65 (-0.80 to -
0.50) and -0,54 (-0.69 to -0.40) respectively (mean difference of -0.10, 95%CI of the difference 
-0.21 to -0.00, p=0.044). Figure 4 (panels a-g) shows the mean daily FLUPro® scores for the 
total symptom burden and individual domains.  The mean change of the FLUPro® domains 
showed that systemic symptoms were significantly greater in BUD compared to UC  
(supplementary table 3). The mean (95%CI) change in CCQ total score between day 0 and 
day 14 in the BUD and UC was -0.49 (-0.63 to -0.35) and -0.37 (-0.51 to -0.24) respectively 
(mean difference of -0.12 (-0.21 to -0.02), p=0.016). The CCQ symptom daily mean score is 
presented as supplementary figure 4.   
The proportion of days with oxygen saturations ≤94%, during the first 14 days, was 19% (SD 
24%) and 22% (SD 27%) in the BUD and UC arm respectively (Wilcoxon test p=0.627; Hodge-
Lehmann median 0 (95% CI (-0.07, 0)). During the first 14 days 59% (n=41) and 58% (n=40) 
in the BUD and UC arms had at least one day with oxygen saturations ≤94% (difference in 
proportions 0.006, 95% CI (-0.158, 0.170), p=0.943).  
The median (IQR) cycle threshold (CT) nasopharyngeal SARS-CoV-2 viral load at Day 0, day 
7 and day 14 was 32.1 (21.7 - 40.0), 35.3 (32.4 - 40.0) and 36.4 (34.2 - 40.0)  respectively. 
There was a significant difference in CT reduction between visit 1 and 2 for both study arms 
(Wilcoxon matched pairs P=0.063 (BUD) and 0.004 (UC), see supplementary figure 5); but 
no difference in reduction between groups (mean (95% CI) change between visit 1 and 2 in 
the BUD and UC was 3.20 (0.46 to 5.94) and 3.75 (1.00 to 6.50) respectively (mean difference 
of -0.55 (95% CI -2.39, 1.29) p=0.554).  
The safety profile of BUD was as expected, with an adverse event reported in 5 participants 
(4 had sore throat; 1 had dizziness). Each of these were all self-limiting and fully resolved on 
cessation of BUD.  
Further analysis  
Stochastic simulations, in a ‘virtual twin’ post-hoc study design, demonstrated that the daily 
odds ratio of reaching the primary outcome, with BUD reduced by 3000% (see figure 5 and 







We have demonstrated that the inhaled glucocorticoid, budesonide, given for a short duration, 
may be an effective treatment of early COVID-19 disease in adults. This effect, with a relative 
reduction of 91% of clinical deterioration is equivalent to the efficacy seen following the use of  
COVID-19 vaccines14 and greater than that reported in any treatments used in hospitalised 
and severe COVID-19 patients15. Our study demonstrated a 14% incidence of urgent 
healthcare need and is consistent with other community based studies16. Our findings indicate 
that the primary outcome events were not mild events, despite occurring in participants with a 
mean age of 45 years with a spectrum of COVID-19 complications from deterioration of a pre-
morbid condition (diabetic ketoacidosis), to the need for prolonged respiratory support. 
Although, there is an indication to target the population at risk of severe illness, such as the 
older and frailer patient with SARS-CoV-2 infection, the real world setting shows that the 
majority of the population that will get COVID-19 are not old and only 9% of the global 
population are over the age of 65 years17. Moreover, it would be unethical to ignore symptoms 
and to omit treatment for a younger person who has a lower population risk of severe COVID-
19. During the study, the local management approach of COVID-19 changed to directing 
patients to COVID-19 hubs as a substitute to ED attendance. Despite this, we could see that 
the majority of the primary outcome events required hospital assessment.   
The broad inclusion criteria make this study intervention relevant to health care systems 
worldwide. Inhaled budesonide is a simple, safe, well studied, inexpensive and widely 
available treatment. The number of participants needed to treat to prevent increased health 
care resource utilization is 8, and combined with the short treatment period required to achieve 
benefit, makes this potentially an affordable and scalable intervention for early COVID-19. 
This is especially significant in low- and middle-income countries where the majority of 
currently approved COVID-19 treatments are unlikely to ever reach patients as a consequence 
of variable healthcare systems18. For example, although dexamethasone is a widely available 
and cheap medicine, with efficacy in reducing mortality in severe and intensive care related 
COVID-1919, and the potential for monoclonal antibody targets in early COVID-195, this is 
unfortunately irrelevant in countries which have limited intensive care, hospital capacity or 
functioning healthcare systems20. Furthermore, in high income countries, inhaled budesonide 
could work as an adjunct to reduce pressure on health care systems until widespread SARS-
CoV-2 vaccination can be achieved. Additionally, the efficacy of inhaled budesonide is unlikely 
to be affected by any emergent SARS-CoV-2 variant which have been a source of concern 
with vaccine implementation21.   
We selected this treatment intervention due to the unexpected observation of an under-
representation of patients with asthma and COPD with severe COVID-1922. This finding from 
early hospitalised cohorts in Wuhan1,2 was at odds with prior respiratory viral pandemics, such 
as H1N1 influenza23. The common therapy between these lung diseases is inhaled 
glucocorticoids, either as a mono-, dual- or triple- constituent. Furthermore, inhaled 
glucocorticoids are among the most prescribed medicine of any class around the world, listed 
by the World Health Organisation (WHO) of essential medicines. Moreover, evidence of the 
utility of inhaled glucocorticoids, in reducing viral exacerbations of asthma have been known 
for many decades24, whilst specifically, inhaled budesonide has shown effect at reducing 
rhinovirus replication in-vitro25. Furthermore, single maintanence and reliever therapy has 
previously been shown to reduce asthma hospitalizations following influenza or the common 
cold (frequently a coronavirus)9; whilst recent reports in asthmatics with SARS-CoV-2 infection 
have repeatedly shown protective effects26-28. The efficacy of dexamethasone in 
RECOVERY19, for severe disease also supports our findings, whilst there is plausibility that 
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the immune-modulatory effect of inhaled glucocorticoids, may also apply to any future viral 
epidemics, but require further evaluation.   
In our study, we found that inhaled budesonide also demonstrated benefit in the secondary 
outcomes, with quicker symptom resolution in those treated with budesonide either measured 
using a self-report of symptom recovery, or defined as normalisation of prospectively collected 
symptom scores measured using the FluPRO®13 or the CCQ12. Of note, there was a 
significantly greater population of participants randomised to budesonide who were free of 
symptoms at 28 days compared to participants randomized to usual care. In the face of the 
evolving nature of chronicity of symptoms following COVID-19 illness, our finding of an impact 
on both patient reported and patient measured symptoms are important29. In the United 
Kingdom, up to 20% of patients30 report persistent symptoms 5 weeks after COVID-19. Our 
findings thus also suggests that intervention with an inhaled glucocorticoid might impact on 
rate of the persistent long-term symptoms in COVID-19 (“long COVID”); and should be 
investigated further in view of the significant long-term health and economic impact of long 
COVID. Excitingly, there are several open-label studies currently open to recruitment 
examining the role of inhaled budesonide in COVID-19 infection (ISRCTN86534580, 
NCT04355637, NCT04331054) and others investigating the role of inhaled ciclesonide 
(NCT04330586, NCT04377711, NCT04381364, NCT04356495); whether these studies also 
demonstrate an impact on long COVID will be of importance 
The positive impact on temperature when used to treat early COVID-19 is further evidence 
that inhaled budesonide is modifying the disease process. Fever has been repeatedly shown 
to be a poor prognostic marker in severe COVID-19 illness1,2 and our findings that budesonide 
signficiantly reduces this by clinical measurement and by anti-pyretic use as a surrogate is 
further supportive that this therapy is likely to be an effective treatment for COVID-19.  
Our study examined the effect on viral titres as a secondary outcome and showed no 
difference between intervention groups. We were unable to demonstrate a mechanistic 
significant difference in reduction in viral load between budesonide and usual care, as per 
previous in-vitro data10. Our study returned lower viral copies (as measured by cycle threshold) 
compared to other studies31, but this is expected in view of the fact that swabs were self-taken, 
where we expect the viral yield to be lower. Moreover, assay sensitivity for detection of SARS-
CoV-2 is recognised to be variable32 and further comparisons taking into consideration the 
natural decay of virus in the nasopharynx to compare against an intervention are warranted.  
Limitations  
Our study design involved randomisation at home, with home visits for study assessments 
and a daily contact until symptom resolution by the study team which limited participant drop-
outs and enhanced the completion of symptom diaries. However, there are limitations to our 
study. Firstly, this is an open-label study, performed out of expediency, where a placebo 
controlled arm was not practical at the time of study inception. In comparison to the awaited 
randomised clinical trials investigating the efficacy of inhaled glucocorticoids (described 
above), with the exception of one (NCT04377711) all are open-label and not placebo 
controlled and thus consistent with our study design. Although there is concern with respect 
to introducing bias, the expected degree of real bias in an open-label study for a new disease 
is unknown. Secondly, the study was stopped early due to the impact of the national pandemic 
control measures, with a second national lockdown, and national prioritisation rules for clinical 
research trials in the UK, which prevented recruitment from outside the local region. Thirdly, 
our study did not reach the sample size. Our power calculations were made from the best 
available predictions in early 2020. Therapeutic randomised clinical trial design and sample 
size calculations are often dictated by statistical assumptions with treatment effect estimations 
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based on the evidence of best available care. However, in trial design for a new disease, with 
no known effective treatment, statistical assumptions are thus arbitrary. We found that the 
budesonide treatment effect size, was larger than predicted; and independent statistical 
simulations concluded that the final sample size and treatment effect had a 99% power to 
reject the null hypothesis. In addition to this, the post-hoc stochastic simulations also provided 
estimations that the effect size could be construed as real; whilst the positive concordance of 
temperature and symptoms as secondary outcomes gives us confidence in our results. These 
aspects were crucial aspects to assess the validity of the study. Our inclusion criteria were 
very general and our study population is younger, with fewer comorbidities than patients that 
are known to have increased mortality2. However, as discussed earlier, our population reflects 
the general global population, in whom we found a 1 in 7 risk of harm from COVID-19, but with 
minor self-limiting side effects of inhaled budesonide. Finally, stopping a study early is unusual 
and is a decision which is not taken without due diligence33. However, we ensured that a priori 
stop decision analysis was performed by an independent statistical team for statistical rigor.  
 
Conclusion 
In conclusion, budesonide, an inhaled glucocorticoid, appears to be an effective treatment for 
early COVID-19 infection which could be applicable to global healthcare systems. Our findings 
require urgent validation and dissemination, especially in the setting of a treatment given early 
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Table 1. Demographics and clinical characteristics of study participants in the per-protocol 
population at study enrollement. 
Characteristic Budesonide (n = 70) Usual care (n = 69) 
Age, years# 44 (19-71) 46 (19-79) 
Female sex, no. (%) 39 (56%) 41 (59%) 
White ethnicity, no. (%) 65 (93%) 64 (93%) 
Body mass index, kg/m2 27 (4.9) 26 (4.6) 
Number of co-morbidities no.¥ 1 (0-2) 1 (0-1) 
Cardiovascular Disease, n (%) 6 (9%) 6 (9%) 
Diabetes, n (%) 3 (4%) 4 (6%) 
Past or current history of Asthma, n (%) 11 (16%) 10 (14%) 
Duration of symptoms, days¥ 3 (2-5) 3 (2-4) 
Evidence of COVID positive status, no. (%) 66 (94%) 65 (94%) 
Presence of symptoms at baseline, no. (%)  
Cough 55 (79%) 48 (70%) 
Fever 49 (70%) 44 (64%) 
Headache 40 (57%) 38 (55%) 
Fatigue 32 (46%) 23 (33%) 
Loss of sense of smell/taste 25 (36%) 30 (43%) 
Gastrointestinal symptoms 11 (16%) 12 (17%) 
Breathlessness 11 (16%) 11 (16%) 
Myalgia 6 (9%) 10 (14%) 
Nasal symptoms 3 (4%) 5 (7%) 
Sore throat 0 (0%) 2 (3%) 
Chest pain/tightness 4 (6%) 1 (1%) 
Other 7 (10%) 8 (12%) 
Highest temperature recorded*¥ 36.6 (36.2- 37.1) 36.6 (35.5-38.3) 
Lowest Oxygenation recorded as % saturation*¥ 96 (95-97) 96 (95-97) 
SARS-CoV-2 viral cycle threshold¥ 32.6 (22.4-39.4) 31.8 (15.6-40.0) 





Figure 1. Consort flow diagram  
Figure 2. Time to self-reported clinical recovery of per protocol population using data 
censoring for primary outcome. BUD = budesonide; UC = usual care 
Figure 3. Violin plots illustrating pooled peak (maximum) temperature in participants in BUD 
and UC arms, with statistically significant difference in the mean temperature (mean difference 
0.49, 95%CI 0.32-0.66, p<0.001). BUD = budesonide; UC = usual care 
Figure 4. Daily mean scores over 14 days using the FLUPro® questionnaire.  Panel (a) total 
symptoms; (b) systemic symtoms (c) nasal symptoms; (d) throat; (e) chest; (f) eyes; (g) 
gastrointestinal. BUD = budesonide; UC = usual care. Vertical bars indicate standard error. 
Figure 5. Relationship between treatment effect, here defined as the daily ratio of the odds of 
reaching primary outcome (PO) in the UC vs BUD arms (horizontal axis) and the ratio of 
primary event outcomes in the UC vs BUD arms at the completion of the trial (vertical axis). 
Plots derived from numerical simulations of the stochastic “virtual twin” trial. These indicate 
that in order to observe our findings (shown by the dotted line), then the daily treatment effect 







Data available for primary outcome analysis 
(n= 69)
Lost to follow-up (give reasons) (n= 0)
Discontinued intervention (give reasons) (n= 0)
Allocated to usual care (n= 73)
Received allocated intervention (n=69)
Did not receive allocated intervention (n=4)
Withdrew consent due to allocation = 3
Needed urgent care prior to visit 1 = 1
Lost to follow-up (give reasons) (n= 0)
Discontinued intervention (too burdensome) (n= 1)
Allocated to budesonide (n=73)
Received allocated intervention (n= 71)
Did not receive allocated intervention (n=2)
Withdrew consent due to allocation = 1
Needed urgent care prior to visit 1 = 1





Assessed for eligibility (n= 167)
Excluded – 21
Prescribed inhaled corticosteroids = 3
Declined = 6
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